Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Medigene ( (DE:MDG1) ) has provided an update.
Medigene AG has announced the pre-release of its financial report for the fiscal year 2024, which will cover the period from January 1, 2024, to December 31, 2024. The report is scheduled to be published online on July 31, 2025. This announcement is part of Medigene’s compliance with financial reporting regulations, and it provides stakeholders with a timeline for when they can expect detailed financial insights, potentially impacting investor decisions and market perceptions.
More about Medigene
Medigene AG is a biotechnology company based in Planegg/Martinsried, Germany. The company is involved in the development of innovative immunotherapies for the treatment of cancer, focusing on T cell receptor-modified T cells (TCR-Ts) and dendritic cell vaccines.
YTD Price Performance: -79.50%
Average Trading Volume: 7,981
Technical Sentiment Signal: Buy
Current Market Cap: €2.97M
For detailed information about MDG1 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue